None listed
Conditions
Interventions
Drug : The experimental and control groups consist of patients undergoing stenting for acute coronary syndrome and will be randomized to receive early evolocumab along with statin/ezetimibe use or no
Sponsors
Yonsei University Yongin Severance Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Over 19 years old (2) Patients who agreed to the research protocol and clinical follow-up survey plan, decided to participate in this study voluntarily, and gave written consent to the informed consent form. (3) Patients who underwent percutaneous coronary stenting for acute coronary syndrome
Exclusion criteria
Exclusion criteria: ? Patients who have previously taken statins, ? Patients with active liver disease or patients with three times or more increase in AST or ALT ? If you have an allergic or hypersensitivity reaction to Evorucumab, statin, or Ezetimib, ? Pregnant women, lactating women, or women of childbearing age who plan to become pregnant during this study ? The remaining life expectancy is expected to be less than a year. ? Subjects who visited the hospital due to psychogenic shock and are expected to be less likely to survive by medical judgment ? Subjects participating in a randomized clinical trial of medical devices/pharmaceuticals
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in LDL level change after 2 weeks of discharge compared to baseline in test group and control group | — |
Secondary
| Measure | Time frame |
|---|---|
| Percent change in LDL level;Presence or absence of side effects (muscle pain, digestive disturbance, test abnormalities);LFT, CK, HbA1c level | — |
Countries
Korea, Republic of
Contacts
Public ContactYONGCHEOL KIM
Yonsei University Yongin Severance Hospital
Outcome results
None listed